2025年4月5日 周六
首页 > 过刊浏览>2025年第65卷第1期 >62-72. DOI:10.13343/j.cnki.wsxb.20240417
PDF HTML阅读 XML下载 导出引用 引用提醒
两种人类Pegivirus致病性研究进展
作者:
基金项目:

广东省自然科学基金(2019A1515010148,2024A1515030275)


Research progress in pathogenicity of two human Pegiviruses
Author:
  • 摘要
    • | |
  • 访问统计
    • |
  • 参考文献 [59]
    • |
  • 相似文献 [20]
    • | | |
  • 文章评论
    摘要:

    目前发现的人类Pegivirus病毒共有2种，这2种病毒本身致病性不强，但均具有独特的生物学特征，可能是病毒学相关研究的重要材料，值得关注。一型人类Pegivirus (the first human Pegivirus,HPgV-1)病毒被称为“good virus”，当其与艾滋病病毒和埃博拉病毒共感染时，可显著减缓相关疾病进程和疾病严重程度。近年来的研究结果发现，该病毒感染还与淋巴瘤和神经系统疾病的发生发展有关，HPgV-1可能会成为艾滋病病毒等引起的、难治愈的病毒病治疗的有效突破点。二型人类Pegivirus (the second human Pegivirus,HPgV-2)病毒于2015年在丙型肝炎患者血液中首次发现，后续研究发现其与丙型肝炎(hepatitis C virus,HCV)病毒感染密切相关，常呈现与HCV共感染，而鲜少形成单独感染。目前，对于HPgV-2与HCV的相互作用机制尚无报道。除此以外，异于大多数RNA病毒，HPgV-2基因组序列表现出高度保守性，种内变异率低，因此，该病毒可能是研究病毒基因组变异规律的理想材料。综上所述，有必要持续关注并针对这2种Pegivirus病毒开展研究。

    Abstract:

    The first human Pegivirus (HPgV-1) and the second human Pegivirus (HPgV-2) are the only two human Pegiviruses that have been identified until now. They share some common features including similar viral genome structure and low pathogenicity, while they also represent unique biological characteristics. HPgV-1 is called “good virus” because of its ability to slow down disease progression and reduce disease severity when co-infecting with HIV and Ebola virus. In addition, HPgV-1 was recently found to be related with lymphoma and neurological diseases. Therefore, HPgV-1 might be a possible breakthrough point in the treatment of refractory diseases caused by HIV and other viruses. HPgV-2 was firstly discovered from the plasma of a hepatitis C virus (HCV)-infected patient in 2015 and was found to always co-infect with HCV but hardly infect healthy people. However, the underlying mechanism of HPgV-2 and HCV co-infection remains to be elucidated. Distinct from most of RNA viruses, HPgV-2 exhibits low genomic diversity with high sequence identity and low intra-host variation, which give the implication of HPgV-2 as an excellent model for studying the mechanisms of viral genome variations. In conclusion, the human Pegiviruses are worthy of sustaining attention and study.

    参考文献
    [1] SIMONS JN, LEARY TP, DAWSON GJ, PILOT-MATIAS TJ, MUERHOFF AS, SCHLAUDER GG, DESAI SM, MUSHAHWAR IK. Isolation of novel virus-like sequences associated with human hepatitis[J]. Nature Medicine, 1995, 1(6): 564-569.
    [2] LEARY TP, MUERHOFF AS, SIMONS JN, PILOT-MATIAS TJ, ERKER JC, CHALMERS ML, SCHLAUDER GG, DAWSON GJ, DESAI SM, MUSHAHWAR IK. Sequence and genomic organization of GBV-C: a novel member of the Flaviviridae associated with human non-A-E hepatitis[J]. Journal of Medical Virology, 1996, 48(1): 60-67.
    [3] KAPOOR A, KUMAR A, SIMMONDS P, BHUVA N, SINGH CHAUHAN L, LEE B, SALL AA, JIN ZZ, MORSE SS, SHAZ B, BURBELO PD, LIPKIN WI. Virome analysis of transfusion recipients reveals a novel human virus that shares genomic features with Hepaciviruses and Pegiviruses[J]. mBio, 2015, 6(5): e01466-15.
    [4] BERG MG, LEE D, COLLER K, FRANKEL M, ARONSOHN A, CHENG K, FORBERG K, MARCINKUS M, NACCACHE SN, DAWSON G, BRENNAN C, JENSEN DM, HACKETT J Jr, CHIU CY. Discovery of a novel human Pegivirus in blood associated with hepatitis C virus co-infection[J]. PLoS Pathogens, 2015, 11(12): e1005325.
    [5] BHATTARAI N, STAPLETON JT. GB virus C: the good boy virus?[J]. Trends in Microbiology, 2012, 20(3): 124-130.
    [6] FAMA A, XIANG JH, LINK BK, ALLMER C, KLINZMAN D, FELDMAN AL, NOWAKOWSKI GS, LIEBOW M, LARSON MC, MAURER MJ, ANSELL SM, NOVAK AJ, ASMANN YW, SLAGER SL, CALL TG, HABERMANN TM, CERHAN JR, STAPLETON JT. Human Pegivirus infection and lymphoma risk and prognosis: a North American study[J]. British Journal of Haematology, 2018, 182(5): 644-653.
    [7] FAMA A, LARSON MC, LINK BK, HABERMANN TM, FELDMAN AL, CALL TG, ANSELL SM, LIEBOW M, XIANG JH, MAURER MJ, SLAGER SL, NOWAKOWSKI GS, STAPLETON JT, CERHAN JR. Human Pegivirus infection and lymphoma risk: a systematic review and meta-analysis[J]. Clinical Infectious Diseases, 2020, 71(5): 1221-1228.
    [8] BALCOM EF, DOAN MAL, BRANTON WG, JOVEL J, BLEVINS G, EDGUER B, HOBMAN TC, YACYSHYN E, EMERY D, BOX A, van LANDEGHEM FKH, POWER C. Human Pegivirus-1 associated leukoencephalitis: clinical and molecular features[J]. Annals of Neurology, 2018, 84(5): 781-787.
    [9] DOAN MAL, ROCZKOWSKY A, SMITH M, BLEVINS G, van LANDEGHEM FKH, GELMAN BB, BRANTON WG, STAPLETON JT, HOBMAN TC, POWER C. Infection of glia by human Pegivirus suppresses peroxisomal and antiviral signaling pathways[J]. Journal of Virology, 2021, 95(23): e0107421.
    [10] SHUI JW, LIU WP, LIANG YH, ZHANG J, WAN ZW, WANG HY, QU XW, TANG SX. Infection of human Pegivirus 2(HPgV-2) is associated with hepatitis C virus but not hepatitis B virus infection in people who inject drugs[J]. The Journal of General Virology, 2019, 100(6): 968-974.
    [11] WANG HY, WAN ZW, XU R, GUAN YJ, ZHU NL, LI JP, XIE ZW, LU AQ, ZHANG FC, FU YS, TANG SX. A novel human Pegivirus, HPgV-2(HHpgV-1), is tightly associated with hepatitis C virus (HCV) infection and HCV/human immunodeficiency virus type 1 coinfection[J]. Clinical Infectious Diseases, 2018, 66(1): 29-35.
    [12] WANG HY, WAN ZW, SUN Q, ZHU NL, LI TY, REN XQ, AN XP, DENG SY, WU Y, LI XF, LI L, LI JY, TONG YG, TANG SX. Second human Pegivirus in hepatitis C virus-infected and hepatitis C virus/HIV-1-co-infected persons who inject drugs, China[J]. Emerging Infectious Diseases, 2018, 24(5): 908-911.
    [13] ANH NT, HONG NTT, NHU LNT, THANH TT, ANSCOMBE C, CHAU LN, THANH TTT, LAU CY, LIMMATHUROTSAKUL D, van VINH CHAU N, van DOORN HR, DENG XT, RAHMAN M, DELWART E, LE T, THWAITES G, van TAN L, Southeast Asia Infectious Disease Clinical Research Network. Detection and characterization of human Pegivirus 2, Vietnam[J]. Emerging Infectious Diseases, 2018, 24(11): 2063-2067.
    [14] RODGERS MA, HOLZMAYER V, VALLARI A, OLIVO A, FORBERG K, FUHRMAN J, COLLER KE, AWAZI B, KENMEGNE SIDJE JB, FRANKEL MB, BERG MG, MBANYA D, NDEMBI N, CLOHERTY GA. Hepatitis C virus surveillance and identification of human Pegivirus 2 in a large Cameroonian cohort[J]. Journal of Viral Hepatitis, 2019, 26(1): 30-37.
    [15] LIANG YH, HU FY, FAN H, LI LH, WAN ZW, WANG HY, SHUI JW, ZHOU YP, TONG YG, CAI WP, TANG SX. Difference of intrahost dynamics of the second human Pegivirus and hepatitis C virus in HPgV-2/HCV-coinfected patients[J]. Frontiers in Cellular and Infection Microbiology, 2021, 11: 728415.
    [16] Fogeda M, Lopez-Alcorocho JM, Bartolome J, Arocena C, Martin MA, Carreno V. Existence of Distinct GB Virus C/Hepatitis G Virus Variants With Different Tropism. J.Virol (2000) 74: 7936-42.
    [17] George SL, Xiang J, Stapleton JT. Clinical Isolates of GB Virus Type C Vary in Their Ability to Persist and Replicate in Peripheral Blood Mononuclear Cell Cultures. Virology (2003) 316: 191-201.
    [18] STAPLETON JT, FOUNG S, MUERHOFF AS, BUKH J, SIMMONDS P. The GB viruses: a review and proposed classification of GBV-A, GBV-C (HGV), and GBV-D in genus Pegivirus within the family Flaviviridae[J]. The Journal of General Virology, 2011, 92(Pt 2): 233-246.
    [19] YU YQ, WAN ZZ, WANG JH, YANG XG, ZHANG CY. Review of human Pegivirus: prevalence, transmission, pathogenesis, and clinical implication[J]. Virulence, 2022, 13(1): 324-341.
    [20] FENG Y, ZHAO WH, FENG YM, DAI JJ, LI Z, ZHANG XY, LIU L, BAI J, ZHANG HT, LU L, XIA XS. A novel genotype of GB virus C: its identification and predominance among injecting drug users in Yunnan, China[J]. PloS one, 2011, 6(10): e21151.
    [21] YANG N, DAI R, ZHANG XJ. Global prevalence of human Pegivirus-1 in healthy volunteer blood donors: a systematic review and meta-analysis[J]. Vox Sanguinis, 2020, 115(3): 107-119.
    [22] WANG TW, CHEN JC, ZHANG Q, HUANG X, XIE NZ, ZHANG JH, CAI TJ, ZHANG Y, XIONG HY. Prevalence of hepatitis G virus infection among 67, 348 blood donors in China[J]. BMC Public Health, 2019, 19(1): 685.
    [23] GRANINGER M, ABERLE S, GÖRZER I, JAKSCH P, PUCHHAMMER-STÖCKL E. Human Pegivirus 1 infection in lung transplant recipients: prevalence, clinical relevance and kinetics of viral replication under immunosuppressive therapy[J]. Journal of Clinical Virology, 2021, 143: 104937.
    [24] SAVASSI-RIBAS F, PEREIRA JG, HORTA MAP, WAGNER TCS, MATUCK TA, MONTEIRO de CARVALHO DB, MELLO FCA, VARELLA RB, SOARES CC. Human Pegivirus-1 infection in kidney transplant recipients: a single-center experience[J]. Journal of Medical Virology, 2020, 92(12): 2961-2968.
    [25] IZUMI T, SAKATA K, OKUZAKI D, INOKUCHI S, TAMURA T, MOTOOKA D, NAKAMURA S, ONO C, SHIMOKAWA M, MATSUURA Y, MORI M, FUKUHARA T, YOSHIZUMI T. Characterization of human Pegivirus infection in liver transplantation recipients[J]. Journal of Medical Virology, 2019, 91(12): 2093-2100.
    [26] LI ZJ, LI YH, LIANG YY, HU LD, CHEN SP. Prevalence and risk factors of human Pegivirus type 1 infection in hematopoietic stem cell transplantation patients[J]. International Journal of Infectious Diseases, 2019, 85: 111-113.
    [27] FOGEDA M, NAVAS S, MARTÍN J, CASQUEIRO M, RODRÍGUEZ E, AROCENA C, CARREŃO V. In Vitro Infection of Human Peripheral Blood Mononuclear Cells by GB Virus C/Hepatitis G Virus[J]. Journal of Virology, 1999, 73: 4052-4061.
    [28] BERG T, MÜLLER AR, PLATZ KP, HӦHNE M, BECHSTEIN WO, HOPF U, WIEDENMANN B, NEUHAUS P, SCHREIER E. Dynamics of GB Virus C Viremia Early After Orthotopic Liver Transplantation Indicates Extrahepatic Tissues as the Predominant Site of GB Virus C Replication[J]. Hepatology, 1999, 29: 245-249.
    [29] BERZSENYI MD, WOOLLARD DJ, McLEAN CA, PREISS S, PERREAU VM, BEARD MR, SCOTT BOWDEN D, COWIE BC, LI S, MIJCH AM, ROBERTS SK. Down-regulation of intra-hepatic T-cell signaling associated with GB virus C in a HCV/HIV co-infected group with reduced liver disease[J]. Journal of Hepatology, 2011, 55(3): 536-544.
    [30] BHANICH SUPAPOL W, REMIS RS, RABOUD J, MILLSON M, TAPPERO J, KAUL R, KULKARNI P, McCONNELL MS, MOCK PA, McNICHOLL JM, ROONGPISUTHIPONG A, CHOTPITAYASUNONDH T, SHAFFER N, BUTERA S. Prevalence and correlates of GB virus C infection in HIV-infected and HIV-uninfected pregnant women in Bangkok, Thailand[J]. Journal of Medical Virology, 2011, 83(1): 33-44.
    [31] FAHNØE U, MADSEN LW, CHRISTENSEN PB, SØLUND CS, MOLLERUP S, PINHOLT M, WEIS N, ØVREHUS A, BUKH J. Effect of direct-acting antivirals on the titers of human Pegivirus 1 during treatment of chronic hepatitis C patients[J]. Microbiology Spectrum, 2024, 12(9): e0064124.
    [32] KÖKSAL MO, PIRKL M, SARSAR K, ILKTAÇ M, HOREMHEB-RUBIO G, YAMAN M, MEŞE S, ERAKSOY H, AKGÜL B, AĞAÇFIDAN A. Interplay between HIV and human Pegivirus (HPgV) load in co-infected patients: insights from prevalence and genotype analysis[J]. Viruses, 2023, 16(1): 5.
    [33] XIANG J, WUNSCHMANN S, DIEKEMA DJ, KLINZMAN D, PATRICK KD, GEORGE SL, STAPLETON JT. Effect of coinfection with GB virus C on survival among patients with HIV infection[J]. The New England journal of medicine 2001, 345(10): 707-714.
    [34] KOEDEL Y, EISSMANN K, WEND H, FLECKENSTEIN B, REIL H. Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition[J]. Journal of Virology, 2011, 85(14): 7037-7047.
    [35] XIANG JH, McLINDEN JH, KAUFMAN TM, MOHR EL, BHATTARAI N, CHANG Q, STAPLETON JT. Characterization of a peptide domain within the GB virus C envelope glycoprotein (E2) that inhibits HIV replication[J]. Virology, 2012, 430(1): 53-62.
    [36] TIMMONS CL, SHAO QJ, WANG CL, LIU L, LIU HL, DONG XH, LIU BD. GB virus type C E2 protein inhibits human immunodeficiency virus type 1 assembly through interference with HIV-1 gag plasma membrane targeting[J]. The Journal of Infectious Diseases, 2013, 207(7): 1171-1180.
    [37] MOHR EL, XIANG JH, McLINDEN JH, KAUFMAN TM, CHANG Q, MONTEFIORI DC, KLINZMAN D, STAPLETON JT. GB virus type C envelope protein E2 elicits antibodies that react with a cellular antigen on HIV-1 particles and neutralize diverse HIV-1 isolates[J]. Journal of Immunology, 2010, 185(7): 4496-4505.
    [38] CHOWDHURY AY, TAVIS JE, GEORGE SL. Human Pegivirus (GB virus C) NS3 protease activity inhibits induction of the type I interferon response and is not inhibited by HCV NS3 protease inhibitors[J]. Virology, 2014, 456: 300-309.
    [39] GEORGE SL, VARMAZ D, TAVIS JE, CHOWDHURY A. The GB virus C (GBV-C) NS3 serine protease inhibits HIV-1 replication in a CD4+ T lymphocyte cell line without decreasing HIV receptor expression[J]. PLoS One, 2012, 7(1): e30653.
    [40] MOENKEMEYER M, SCHMIDT RE, WEDEMEYER H, TILLMANN HL, HEIKEN H. GBV-C coinfection is negatively correlated to Fas expression and Fas-mediated apoptosis in HIV-1 infected patients[J]. Journal of Medical Virology, 2008, 80(11): 1933-1940.
    [41] LAUCK M, BAILEY AL, ANDERSEN KG, GOLDBERG TL, SABETI PC, O’CONNOR DH. GB virus C coinfections in west African Ebola patients[J]. Journal of Virology, 2015, 89(4): 2425-2429.
    [42] OGUZIE JU, PETROS BA, OLUNIYI PE, MEHTA SB, EROMON PE, NAIR P, ADEWALE-FASORO O, IFOGA PD, ODIA I, PASTUSIAK A, GBEMISOLA OS, AIYEPADA JO, UYIGUE EA, EDAMHANDE AP, BLESSING O, AIRENDE M, TOMKINS-TINCH C, QU J, STENSON L, SCHAFFNER SF, et al. Metagenomic surveillance uncovers diverse and novel viral taxa in febrile patients from Nigeria[J]. Nature Communications, 2023, 14: 4693.
    [43] AGI E, HOJJATIPOUR S, NAMVAR A, BOLHASSANI A. Impact of blood transfusion on the prevalence of HHpgV-1, HPgV-1, and B19V among Iranian HCV-infected patients with hemophilia[J]. Journal of Pediatric Hematology/Oncology, 2020, 42(4): e213-e218.
    [44] ZHU NL, XU R, TANG WP, WANG HY, WAN ZW, WU XD, FU YS, TANG SX, YU SY. Detection of a novel human Pegivirus HPgV-2 in healthy blood donors and recipients of multiple transfusions: implications for blood safety[J]. Journal of Southern Medical University, 2018, 38(7): 842-849.
    [45] BONSALL D, GREGORY WF, IP CLC, DONFIELD S, ILES J, ANSARI MA, PIAZZA P, TREBES A, BROWN A, FRATER J, PYBUS OG, GOULDER P, KLENERMAN P, BOWDEN R, GOMPERTS ED, BARNES E, KAPOOR A, SHARP CP, SIMMONDS P. Evaluation of viremia frequencies of a novel human Pegivirus by using bioinformatic screening and PCR[J]. Emerging Infectious Diseases, 2016, 22(4): 671-678.
    [46] TANG SX, WANG HY. Presence of human Hepegivirus-1 in a cohort of people who inject drugs[J]. Annals of Internal Medicine, 2018, 168(2): 157-158.
    [47] WAN ZW, LIU JW, HU FY, SHUI JW, LI LH, WANG HY, TANG XP, HU CG, LIANG YH, ZHOU YP, CAI WP, TANG SX. Evidence that the second human Pegivirus (HPgV-2) is primarily a lymphotropic virus and can replicate independent of HCV replication[J]. Emerging Microbes & Infections, 2020, 9(1): 485-495.
    [48] CHEN SY, WANG HY, DZAKAH EE, RASHID F, WANG JF, TANG SX. The second human Pegivirus, a non-pathogenic RNA virus with low prevalence and minimal genetic diversity[J]. Viruses, 2022, 14(9): 1844.
    [49] CHEN SY, WU JQ, YANG XF, SUN QL, LIU S, RASHID F, DZAKAH EE, WANG HY, WANG JF, GONG P, TANG SX. RNA-dependent RNA polymerase of the second human Pegivirus exhibits a high-fidelity feature[J]. Microbiology Spectrum, 2022, 10(5): e0272922.
    [50] SIBLEY SD, LAUCK M, BAILEY AL, HYEROBA D, TUMUKUNDE A, WENY G, CHAPMAN CA, O’CONNOR DH, GOLDBERG TL, FRIEDRICH TC. Discovery and characterization of distinct simian Pegiviruses in three wild African Old World monkey species[J]. PLoS One, 2014, 9(2): e98569.
    [51] PFAENDER S, CAVALLERI JMV, WALTER S, DOERRBECKER J, CAMPANA B, BROWN RJP, BURBELO PD, POSTEL A, HAHN K, ANGGAKUSUMA, RIEBESEHL N, BAUMGÄRTNER W, BECHER P, HEIM MH, PIETSCHMANN T, FEIGE K, STEINMANN E. Clinical course of infection and viral tissue tropism of hepatitis C virus-like nonprimate Hepaciviruses in horses[J]. Hepatology, 2015, 61(2): 447-459.
    [52] QUAN PL, FIRTH C, CONTE JM, WILLIAMS SH, ZAMBRANA-TORRELIO CM, ANTHONY SJ, ELLISON JA, GILBERT AT, KUZMIN IV, NIEZGODA M, OSINUBI MOV, RECUENCO S, MARKOTTER W, BREIMAN RF, KALEMBA L, MALEKANI J, LINDBLADE KA, ROSTAL MK, OJEDA-FLORES R, SUZAN G, et al. Bats are a major natural reservoir for Hepaciviruses and Pegiviruses[J]. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110(20): 8194-8199.
    [53] KAPOOR A, SIMMONDS P, SCHEEL TKH, HJELLE B, CULLEN JM, BURBELO PD, CHAUHAN LV, DURAISAMY R, SANCHEZ LEON M, JAIN K, VANDEGRIFT KJ, CALISHER CH, RICE CM, LIPKIN WI. Identification of rodent homologs of hepatitis C virus and Pegiviruses[J]. mBio, 2013, 4(2): e00216-13.
    [54] WU Z, WU YY, ZHANG W, MERITS A, SIMMONDS P, WANG MS, JIA RY, ZHU DK, LIU MF, ZHAO XX, YANG Q, WU Y, ZHANG SQ, HUANG J, OU XM, MAO S, LIU YY, ZHANG L, YU YL, TIAN B, et al. The first nonmammalian Pegivirus demonstrates efficient in vitro replication and high lymphotropism[J]. Journal of Virology, 2020, 94(20): e01150-20.
    [55] BAILEY AL, BUECHLER CR, MATSON DR, PETERSON EJ, BRUNNER KG, MOHNS MS, BREITBACH M, STEWART LM, ERICSEN AJ, NEWMAN CM, KOENIG MR, MOHR E, TAN J, CAPUANO S 3rd, SIMMONS HA, YANG DT, O’CONNOR DH. Pegivirus avoids immune recognition but does not attenuate acute-phase disease in a macaque model of HIV infection[J]. PLoS Pathogens, 2017, 13(10): e1006692.
    [56] TOMLINSON JE, WOLFISBERG R, FAHNØE U, SHARMA H, RENSHAW RW, NIELSEN L, NISHIUCHI E, HOLM C, DUBOVI E, ROSENBERG BR, TENNANT BC, BUKH J, KAPOOR A, DIVERS TJ, RICE CM, van de WALLE GR, SCHEEL TKH. Equine Pegiviruses cause persistent infection of bone marrow and are not associated with hepatitis[J]. PLoS Pathogens, 2020, 16(7): e1008677.
    [57] XIANG J, WÜNSCHMANN S, SCHMIDT W, SHAO J, STAPLETON JT. Full-length GB virus C (hepatitis G virus) RNA transcripts are infectious in primary CD4-positive T cells[J]. Journal of Virology, 2000, 74(19): 9125-9133.
    [58] NENNIG K, MURTHY S, MALONEY S, SHAW TM, SHAROBIM M, MATKOVIC E, FADIRAN S, LARSEN M, RAMUTA MD, KIM AS, TEIJARO JR, GROVE J, STREMLAU M, SHARMA H, TRIVEDI S, BLUM MJ, O’CONNOR DH, HYDE JL, STAPLETON JT, KAPOOR A, BAILEY AL. Determinants of Pegivirus persistence, cross-species infection, and adaptation in the laboratory mouse[J]. PLoS Pathogens, 2024, 20(8): e1012436.
    [59] 万政伟. 人持续性G病毒二型在中国人群中的检出及其感染性克隆初步探索[D]. 广州: 南方医科大学博士学位论文, 2021. WAN ZW. Detection of the novel human pegivirus type 2 in China and preliminary exploration of its infectious clone[D]. Guangzhou: Doctoral dissertation of Southern Medical University, 2021(in Chinese).
    引证文献
引用本文

陈淑仪,万政伟,丘丽,王海鹰. 两种人类Pegivirus致病性研究进展[J]. 微生物学报, 2025, 65(1): 62-72

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2024-07-10
  • 在线发布日期: 2025-01-04
  • 出版日期: 2025-01-04
文章二维码

科微学术

微生物学报

您是本站第 5590234 访问者

通信地址：北京市朝阳区北辰西路1号院3号 中国科学院微生物研究所   邮编：100101

电话：010-64807516    E-mail：actamicro@im.ac.cn

版权所有：微生物学报 ® 2025 版权所有